Europe's economic crisis has created a new reality. Austerity measures at the national level have placed an even higher premium than in the past on controlling healthcare costs, resulting in an increasingly tough reimbursement environment and a contraction of the European pharmaceutical market.

BioCentury's 11th annual European Iceberg survey shows investors are clearly adapting, but they say some young companies are still resisting reality.